B

Bristol Myers Squibb

Makes drugs for cancer, blood and immune diseases

Executive Director - Strategy & Commercial Development, Neuroscience

Full-TimeUpdated on 10/24/2026Deadline 11/9/26
$239.1k - $289.7k+ Discretionary incentive cash + Stock opportunities
Expert
Bachelor's, Master's, MBA
Princeton, NJ, USA
In PersonDomestic and international travel required (~20%).
Growth & MarketingProduct Marketing
Company Historically Provides H1B Sponsorship

About the job

Requirements
  • A bachelor's degree is required; a life sciences degree or equivalent is desirable, and an MBA or graduate degree is highly preferred.
  • At least 12 years of progressive industry experience with a proven track record across products in various stages of development, from pipeline to launch to in-market.
  • Demonstrated scientific acumen and understanding of drug development processes, regulatory pathways, product design, and new product evaluation.
  • Understanding of commercial drug development, including global and country market dynamics, operational feasibility, market access, patient advocacy, and regulatory and reimbursement challenges across domestic and international markets.
  • Demonstrated people-leadership experience, including managing and developing direct reports.
  • Ability to critically assess opportunities, determine what is best for patients and the business, and influence and build alignment with stakeholders.
  • Strong financial acumen, including the ability to assimilate complex information, create and manage budgets, and meet financial targets.
  • Proven breadth and depth of experience across marketing competencies and achievement of performance objectives.
  • Experience leading strategically, communicating with impact, and creating an inclusive and energizing culture consistent with company values.
  • Experience mobilizing matrix team members and working within a cross-functional environment.
  • Knowledge of artificial intelligence resources and how to use them to enhance productivity and quality outputs.
Responsibilities
  • Lead worldwide brand planning and long-range forecasting across the neurodegeneration pipeline, including assets from Discovery through Phase 2b/3 in Alzheimer's, Parkinson's, and other neurodegenerative conditions.
  • Own neurodegeneration market development, including biomarker and diagnosis strategy, patient identification pathways, and market preparation for launch.
  • Set the strategic direction for neurodegeneration and ensure day-to-day execution aligns with the overall franchise strategy.
  • Assess competitive data and events, identify emerging trends that could affect brands, and integrate the implications into brand strategy and plans in rapidly evolving areas new to the organization.
  • Translate new clinical and scientific evidence into brand strategy to maximize opportunities for appropriate patient usage.
  • Partner with opinion leaders, advocacy groups, external agencies, and other stakeholders to reinforce the organization's commitment to neurodegeneration and build its presence in these areas.
  • Partner with the worldwide Value, Access, and Pricing team to optimize access and uptake at launch through development strategies that meet future market needs.
  • Build understanding of local market dynamics, including customer and competitive insights, and identify growth opportunities to drive global development and launch.
  • Lead and influence across functions and levels to guide development for future commercial success.
  • Develop the strategic and long-range plan for neurodegeneration, guide products through key stage-gate transitions, and represent key products to Executive Management.
  • Develop strategies and stakeholder relationships to establish the organization's presence in new neurodegeneration therapeutic areas.
  • Lead commercial teams and represent commercial interests on Global Program Teams.
  • Represent key products at the Global Program Team level and provide overall commercial direction for the neurodegeneration area.
  • Establish strategic platforms to prepare the market for launch, shape biomarker and diagnosis strategy, and build relationships with patient advocacy organizations, medical societies, and thought leaders.
  • Define commercialization strategies, understand customer and market dynamics, and prepare for launches in emerging therapeutic spaces.
  • Partner with Development, Medical, Regulatory, CMC, Commercial, and Project Leadership to optimize development strategy, brand development, and market preparation for each asset; work with key markets, Business Insights & Analytics, and Value, Access & Pricing to incorporate commercial input into product development decisions.
  • Identify growth opportunities and seek opportunities within and beyond the organization to add value to long-term plans.
  • Travel domestically and internationally approximately 20%.
Desired Qualifications
  • US and global experience.
  • Functional experience in Alzheimer's disease and/or movement disorders, including Parkinson's disease or Dementia with Lewy Bodies.

About the company

Bristol Myers Squibb discovers, develops and sells prescription medicines for serious illnesses, including cancer, blood disorders, immune diseases and heart disease, for patients treated by doctors and hospitals around the world. Its best-known drug is Opdivo, an immunotherapy that helps the body's own immune system find and attack many kinds of cancer. Researchers develop drug candidates in its labs or bring them in through acquisitions and partnerships, then test them in clinical trials to win regulatory approval. The company makes and markets the approved medicines and earns its revenue from sales of patent-protected drugs. Its roots go back to a business founded in 1887, and it is based in Lawrence Township, New Jersey.

Company Size

10,001+

Company Stage

IPO

Headquarters

Lawrence Township, New Jersey

Founded

1887

Get referred to Bristol Myers Squibb

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sales are beating forecasts: BMS raised 2026 revenue guidance to $49 billion to $50 billion in July 2026.
  • Newer drugs carry the business: they made $7.6 billion of $13.0 billion in sales in the June 2026 quarter.
  • Manufacturing careers are expanding: a $2.3 billion Houston campus announced in August 2026 will add nearly 500 skilled roles.

What critics are saying

  • Job security is shaky: BMS added 265 New Jersey layoffs in September 2026, bringing its 2026 state cuts to 718.
  • A patent cliff looms: Eliquis and Opdivo, its two biggest drugs, lose US exclusivity around 2028.
  • Older drugs are shrinking fast: Revlimid sales fell 49% to $425 million in the June 2026 quarter as generics spread.

What makes Bristol Myers Squibb unique

  • BMS owns a psychiatry first: Cobenfy treats schizophrenia without blocking dopamine, unlike antipsychotics used for decades.
  • Its top seller is shared: BMS splits Eliquis blood thinner profits roughly equally with Pfizer in most markets.
  • BMS reengineers patients' own immune cells: it sells two CAR T therapies, Breyanzi and Abecma, for blood cancers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours
  • Hybrid Work Options
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

8%

1 year growth

7%

2 year growth

7%
Yahoo Finance
Oct 23rd, 2026
Three defensive stocks to buy as AI selloff hits: BMY, Colgate and Gilead offer dividends

As investors question the costs and returns of the AI boom, some are turning to defensive stocks in healthcare and consumer goods. Three that pay quarterly dividends stand out: Bristol Myers Squibb, Colgate-Palmolive, and Gilead Sciences. Bristol Myers Squibb shares are up 14.3% this year, with a forward dividend yield of 4.3% and 18 straight years of increases. Second-quarter revenue reached $13 billion, with newer products making up nearly 60%. Colgate-Palmolive is up 20.2% this year and has raised its dividend for 64 years in a row. It reported second-quarter revenue of $5.36 billion. Gilead shares have gained 26%, against 13% for the S&P 500. Second-quarter HIV sales rose 12% to $5.7 billion.

Market Chameleon
Oct 19th, 2026
Bristol Myers to bring 12 oral presentations and nearly 60 oncology disclosures to ESMO 2026.

Bristol Myers to bring 12 oral presentations and nearly 60 oncology disclosures to ESMO 2026. 19 October 2026, 8:50 AM By Market Chameleon Produced with AI assistance and reviewed by Market Chameleon staff. Bristol Myers Squibb (BMY) said it will present new data across its oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) 2026 Congress (October 23-27 in Madrid), spanning 12 oral presentations and nearly 60 disclosures. The company's update spotlights multiple modalities across solid tumors, including late-breaking Phase 3 studies for izalontamab brengitecan (iza-bren) and late-breaking global Phase 2 data for pumitamig, alongside long-term survival results for Opdivo plus Yervoy. ESMO 2026 presence emphasizes late-breaking Phase 3 and Phase 2 catalysts across solid tumors. In the announcement, Bristol Myers highlighted two late-breaking, Phase 3 studies of izalontamab brengitecan (iza-bren), described as a potential first-in-class EGFR x HER3 bispecific antibody-drug conjugate (ADC), in EGFR-mutated non-small cell lung cancer (PANKU-Lung01) and HR+/HER2- breast cancer (PANKU-Breast01).

Savills
Oct 14th, 2026
San diego Q3 2026 life sciences market report.

San diego Q3 2026 life sciences market report. 14 October 2026 Market highlights. * Overall vacancy increased 60 basis points year over year to 28.5% in Q3 2026, up from 27.9% in Q3 2025. The increase was driven by direct vacancy, which rose to 25.8%, while sublease vacancy declined to 2.8%. * Venture capital funding slowed considerably in 2026, with $1.4 billion raised across 113 deals through Q3, down 34.1% year over year and marking the lowest Q1 through Q3 total since 2022. * Alexandria Real Estate delivered a 427,000-square-foot R&D hub for Bristol Myers Squibb at Campus Point, establishing the company as an anchor tenant at the 2.9- million-square-foot life sciences campus.

Yahoo Finance
Oct 13th, 2026
Eli Lilly beats Bristol Myers Squibb on growth: $65.2B revenue, 45% rise vs. $48.2B

A comparison of Bristol Myers Squibb and Eli Lilly concludes that Lilly is the better healthcare stock to buy in 2026, even at a premium. Lilly's 2025 revenue rose about 45% to $65.2 billion, with net income near $21 billion. Bristol Myers' revenue slipped 0.2% to $48.2 billion, though it returned to a net income of $7.1 billion after an $8.9 billion loss in 2024. Lilly trades at 33.8 times forward earnings against 8.2 times for Bristol Myers. The article says Bristol Myers is cheap for good reason, citing pricing pressure, patent expiries, and an unpredictable recovery. Lilly's weight-loss drugs Zepbound and Mounjaro are expected to lift 2026 revenue above 30%, to $88.6 billion. Bristol Myers is forecast to grow 3% to $49.9 billion.

Chinese LGZ
Oct 9th, 2026
Bristol Myers Squibb unveils $2.3 billion investment in cutting-edge Houston pharma facility.

Bristol Myers Squibb unveils $2.3 billion investment in cutting-edge Houston pharma facility. Source link: https://houston365.info/2026/10/09/bristol-myers-squibb-unveils-2-3-billion-investment-in-cutting-edge-houston-pharma-facility/ Bristol Myers Squibb strengthens Houston's life sciences sector with $2.3 billion facility. Bristol Myers Squibb is set to transform Houston's pharmaceutical landscape through a landmark $2.3 billion investment in a cutting-edge manufacturing plant. This initiative, developed in collaboration with the Greater Houston Partnership, aims to elevate the company's production capabilities while cementing Houston's status as a burgeoning center for biopharmaceutical innovation. The project is projected to generate hundreds of skilled jobs and stimulate substantial economic growth within the region. Project overview and strategic importance. The new facility will incorporate the latest manufacturing technologies to optimize efficiency and product quality. With over 1,200 new roles anticipated in scientific research, engineering, and production, the plant will serve as a catalyst for workforce development and community engagement. This expansion aligns with Bristol Myers Squibb's vision to accelerate the delivery of novel therapies and reinforces Houston's growing influence in the life sciences ecosystem. * Innovative manufacturing processes: Adoption of advanced automation and quality control systems. * Employment opportunities: Creation of more than 1,200 specialized jobs across multiple disciplines. * Community collaboration: Strengthening partnerships with local universities and healthcare institutions to foster innovation. | Investment Detail | Information | | Total... | - - Author: Samuel Brown Publish date: 2026-10-09 15:23:00 Copyright for syndicated content belongs to the linked Source. - - 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8